louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02104310: A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas
Official title: A Pilot Study Evaluating the Utility of 18F-DOPA PET for Radiotherapy Treatment Planning of Malignant Glioma Patients
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Malignant Glioma
Keywords: malignant glioma
FDOPA
PET CT
radiation therapy
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Brains Together for the Cure
First posted: 2014-04-04
Enrollment: 25
Sex: ALL
Minimum age (years): 7
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Newly diagnosed or recurrent WHO Grade II and Grade III Glioma patients.

Brief summary: For most brain tumors, radiation treatment is guided by a Magnetic Resonance Imaging (MRI) scan. In this study, information from a special scan, called a Positron Emission Tomography/ Computed Tomography (PET/CT) scan using an amino acid called Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) will also be used. This type of scan has shown promise in being able to better distinguish tumor from normal brain tissue and may help to more accurately plan radiation treatment. This type of scan can also assist the radiation oncologist in identifying the most aggressive regions of the tumor. The goal of this study is to compare the 18F-DOPA PET/CT scan with the MRI scan for identifying where the disease is that needs to be treated with radiation.


Eligibility criteria: Inclusion Criteria:

* Age ≥7 years.
* Biopsy confirmed newly diagnosed or recurrent WHO Grade II or Grade III malignant glioma.
* CT simulation, 18F-DOPA PET imaging, and standard of care pre-radiotherapy MRI scans to be performed at Mayo Clinic Rochester.
* Willing to sign release of information for any follow-up records.
* Provide informed written consent.

Exclusion Criteria:

* Patients diagnosed with WHO grade IV malignant glioma.
* Patients previously treated with radiation therapy.
* Unable to undergo MRI scans with contrast (e.g. cardiac pacemaker, defibrillator, kidney failure).
* Unable to undergo an 18F-DOPA PET scan (e.g. Parkinson's Disease, taking anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists)
* Pregnant women
* Nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception

Primary outcomes:
measure: Treatment volume comparison
timeFrame: 6 weeks
Secondary outcomes:
measure: Advanced imaging volume comparison
timeFrame: 6 weeks
measure: Concordance with recurrence
timeFrame: up to 10 years
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Nadia N Laack, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Mayo Clinic
name: Debra Brinkmann, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Mayo Clinic
name: Deanna Pafundi, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00665210: Digital Sizing for Orthopaedic Hip Implants
Official title: Photo-manipulation of Digital Radiographs and Digitized Templates as a Method for Preoperative Sizing of Total Hip Arthroplasties
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hip Arthritis
Keywords: hip arthritis
implant sizing
Lead sponsor: Ottawa Hospital Research Institute
Sponsor class: OTHER
First posted: 2008-04-23
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients booked for primary total hip arthroplasty with non-cemented prosthesis

Brief summary: Hip implants come in different sizes. Currently, surgeons predict the implant size that will be needed using an analogue method whereby photos of the implant sizes are overlaid on the x-rays. In this study, we propose to use a digital, computerized method of templating which we expect will be more accurate than the overlay method.


Eligibility criteria: Inclusion Criteria:

* Patients booked for primary total hip arthroplasty with non-cemented prosthesis.
* No previous surgery/fractures to acetabulum or femur or hip.
* No gross bony abnormality except for osteoarthritis and avascular necrosis.

Exclusion Criteria:

* Cancer or tumor suspected, morbid obesity, revision, previous acetabular/femur/hip surgery, gross bony deformity, calibration bar not completely pictured on radiograph, unsuccessful surgery fracture/cancer/cemented prosthesis used.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: OHRI
state: Ontario
Study officials:
affiliation: Ottawa Hospital Research Institute
name: Peter Thurston, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02160210: Ultrafine Endoscope for Colonoscopy in Diagnosis of Colorectal Diseases
Official title: Ultrafine Endoscope for Unsedated Colonoscopy is an Effective Method to Reduce Abdominal Pain:a Prospective Randomized Study.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Colon Disease;
Rectal Disease
Lead sponsor: First Affiliated Hospital of Harbin Medical University
Sponsor class: OTHER
First posted: 2014-06-10
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study is the evaluation of ultrafine endoscope (with small caliber and turning radius )for colonoscopy in decreasing abdominal pain of patients . 60 patients will be accepted in this trial.

Detailed description: The aim of this study is to investigate the advantages of an endoscope with smaller turning radius and softer insert section in reducing patients' abdominal pain in colonoscopy. Transnasal gastroscope was selected in this study , because of its small caliber (5.9mm) and small turning radius . Visual analogue scale(VAS),cecum intubation time and cecum intubation rate were evaluated.

Eligibility criteria: Inclusion Criteria:

1. Patients diagnostic colonoscopy;
2. Subjects able to provide informed consent

Exclusion Criteria:

1. Patients with poor bowel preparation;
2. Contraindications of the colonoscopy;
3. Prior partial or complete colectomy

Primary outcomes:
measure: VAS abdominal pain scores
timeFrame: up to two months
Secondary outcomes:
measure: Cecum intubation time
timeFrame: up to two months
measure: The time to reach the splenic flexure
timeFrame: up to two months
measure: The time to reach the hepatic flexure
timeFrame: up to two months
measure: The success rate of the cecal intubation within 15 minutes
timeFrame: up to two months
Other outcomes:
Locations:
city: Harbin
country: China
facility: The Gastroenterology Department of The 1st Affiliated Hospital of Harbin Medical University
state: Heilongjiang
Study officials:
affiliation: Gastroenterology Department of The 1st Affiliated Hospital of Harbin Medical University
name: Youlin Yang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06943014: Development and Validation of an Actimetric Protocol to Quantify Physical Activity and Sedentary Behaviour in Post-stroke Subjects
Official title: Development and Validation of an Actimetric Protocol to Quantify Physical Activity and Sedentary Behaviour in Post-stroke Subjects
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Stroke
Chronic Stroke Patients
Stroke With Hemiparesis
Keywords: Physical activity monitoring
Stroke rehabilitation
Actimetry
Accelerometers
Pressure insoles
Energy expenditure estimation
Inactivity tracking
Actimetry to measure physical activity and sedentary behavior in stroke patients
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2025-04-24
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The aim of this project is to develop an actimetry protocol based on a system of motion sensors, such as accelerometers and pressure insoles.

These sensors will be used to analyze arm and leg movements in individuals who have experienced a stroke. Throughout the study, we will adjust certain parameters-such as sensor placement and measurement frequency-to optimize data quality.

We will also refine data analysis methods to better identify the types of movements performed (upper and lower limbs), estimate energy expenditure, and recognize different postures adopted by the participant (sitting, standing, etc.).

The goal of this protocol is to provide accurate measurements of physical activity and inactivity, both in controlled environments (such as a laboratory) and in real-life settings (outdoors or at home).

This study will allow us to validate the reliability of the actimetry protocol and assess how easy it is to use at home.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Stroke diagnosed by a neurologist and confirmed by medical imaging
* More than 14 days post-stroke
* Medically stable condition
* Hemiparesis with impaired locomotion: Functional Ambulation Classification (FAC) between 1 and 5
* Montreal Cognitive Assessment (MoCA) score \> 18/30

Exclusion Criteria:

* Inability to understand simple instructions
* Other neurological or musculoskeletal disorders limiting functional mobility

Primary outcomes:
measure: Actimetry protocol
timeFrame: By the completion of the home monitoring phase, expected around April 2027
Secondary outcomes:
measure: Validation, feasibility, and usability of the actimetry protocol across different environments
timeFrame: By the completion of the home monitoring phase, expected around April 2027
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Cliniques universitaires Saint-Luc
Study officials:
affiliation: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
name: Thierry Lejeune
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06494514: NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer
Official title: A Single-center, Randomized, Interventional Controlled Study of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy for First-line Treatment of Locally Advanced Pancreatic Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Locally Advanced Pancreatic Cancer
Lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sponsor class: OTHER
First posted: 2024-07-10
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systematical therapy in patients with ocally advanced pancreatic cancer.


Eligibility criteria: Inclusion Criteria:

1. Histologically or cytologically confirmed pancreatic cancer;
2. ECOG performance no more than 2;
3. Radiographically assessed as locally advanced pancreatic cancer according to NCCN guidelines;
4. No previous anti-tumor therapy；
5. Able and willing to provide a written informed consent;

Exclusion Criteria:

* 1. Prior anti-tumor therapy of any kind; 2. Severe infection (\>NCI CTC grade 2); 3.Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs; 4.Patients with bleeding tendency; 5. Pregnant or lactating women.

Primary outcomes:
measure: mPFS
timeFrame: Up to 12 months
Secondary outcomes:
measure: mOS
timeFrame: Up to 24 months
measure: ORR
timeFrame: Up to 12 months
measure: DCR
timeFrame: Up to 12 months
Other outcomes:
Locations:
city: Nanjing
country: China
facility: FirstNanjingMU
state: Jiangsu
city: Nanjing
country: China
facility: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
state: Jiangsu
Study officials:
affiliation: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
name: Juan Du
role: PRINCIPAL_INVESTIGATOR
affiliation: The First Affiliated Hospital with Nanjing Medical University
name: Min Tu
role: STUDY_DIRECTOR
References:
Clinical trial NCT05340114: Usability Study of CEREBO® - A Novel Non-invasive Intracranial Bleed Detector
Official title: Summative Usability Study of CEREBO® in Traumatic Brain Injury Patients to Determine Ease of Use, Ease of Learning and Satisfaction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Traumatic Brain Injury
Intracranial Hemorrhages
Keywords: Ease of Use
Ease of Learning
Satisfaction
Lead sponsor: Bioscan Research Pvt. Ltd.
Sponsor class: INDUSTRY
First posted: 2022-04-21
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: Traumatic Brain Injury (TBI) is the leading cause of death and disability across the globe. Time from injury to treatment is the most critical factor that determines the patient's recovery. Mild TBI with no apparent symptoms are often left undiagnosed, thus delaying the treatment and hence recovery. CEREBO® is a non-invasive, rapid, near-infrared based, point-of-care device that can detect an intracranial bleed at an early stage.

Detailed description: This prospective study determines the usability of CEREBO® to detect the intracranial hematoma. The operators will receive a training session before the study and will be evaluated at the end of the study through a survey questionnaire for ease of use, ease of learning and satisfaction. Each operator will examine at least 10 subjects with CEREBO®.

Eligibility criteria: Inclusion Criteria:

Operators -

Medical health professionals \>18 years of age with a valid medical license to practice medicine belonging to one of the following categories and have given a written consent to participate in the study.

1. MBBS with Specialisation
2. MBBS
3. Nursing Staff
4. Others

Subjects -

1. Subjects with suspected traumatic brain injury and GCS \> 13
2. Of all ages and gender, have understood the study and gave a written informed consent.

Exclusion Criteria:

Subjects -

1. Subjects with active bleeding or scalp laceration
2. Subjects with large extracranial lesions

Primary outcomes:
measure: To evaluate the summative usability of CEREBO®
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Civil Hospital India
name: Dr. Jaimin Shah
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02928614: Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance
Official title: Biomarkers in Obese Patients With Knee Osteoarthritis Following Long-term Weight Maintenance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Osteoarthritis
Obesity
Keywords: Osteoarthritis
Obesity
Liraglutide 3 mg
Liraglutide
Biomarkers
Lead sponsor: Parker Research Institute
Sponsor class: OTHER
First posted: 2016-10-10
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a substudy to a randomized trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864). In the parent trial, patients will be subjected to an 8-week diet intervention phase including a low-calorie diet and dietetic counseling, after which they will be randomized to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle.

This substudy aims to investigate the impact of, and subsequent change of biomarkers in obese patients with knee osteoarthritis following a randomization to Liraglutide 3 mg or Liraglutide 3 mg placebo treatment between weeks 0-52.


Eligibility criteria: Inclusion Criteria:

* Same as parent trial (NCT02905864)

Exclusion Criteria:

* Same as parent trial (NCT02905864)

Primary outcomes:
measure: Change in collagen II degradation fragment α-C2M
timeFrame: Week 0 to 52
Secondary outcomes:
measure: Change in collagen II degradation fragment β-C2M
timeFrame: Week 0 to 52
measure: Change in non-coding RNA type snoRNAs U38 and U48
timeFrame: Week 0 to 52
measure: Change in miRNA-454
timeFrame: Week 0 to 52
measure: Change in miRNA let-7e
timeFrame: Week 0 to 52
measure: Change in Nesfatin-1
timeFrame: Week 0 to 52
Other outcomes:
Locations:
city: Frederiksberg
country: Denmark
facility: The Parker Institute
state: Capital Region
Study officials:
References:
Clinical trial NCT01138514: Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels
Official title: A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo Israel Pharmaceuticals, Ltd., Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to a Comparator Clindamycin / Benzoyl Peroxide Topical Gel, and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Acne Vulgaris
Lead sponsor: Padagis LLC
Sponsor class: INDUSTRY
First posted: 2010-06-07
Enrollment: 1555
Sex: ALL
Minimum age (years): 12
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the efficacy and safety profiles of Perrigo Israel Pharmaceuticals, Ltd. Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel and Benzaclin® Topical Gel (Clindamycin- Benzoyl Peroxide Gel).


Eligibility criteria: Inclusion Criteria:

* Healthy men or women, 12 to 65 years of age
* Willing to participate and sign provide written consent
* Moderate to severe acne

Exclusion Criteria:

* Pregnant or lactating women
* History of unresponsiveness or hypersensitivity to clindamycin, benzoyl peroxide or lincomycin
* Use of systemic, topical or facial products which may interfere with the study
* Participation in any clinical study in the 30 days prior to study entry
* Prolonged exposure to sunlight or excessive exposure to UV lights
* Chronic use of NSAIDS

Primary outcomes:
measure: Percent Change From Baseline in Inflammatory Lesions
timeFrame: 10 weeks
measure: Percent Change From Baseline in Non-inflammatory Lesions
timeFrame: 10 weeks
Secondary outcomes:
measure: Number of Participant With Clinical Success on the Investigator's Global Assessment (IGA)
timeFrame: 10 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03824314: Effect of Adding Midazolam Versus Fentanyl to Intrathecal Levobupivacaine in Patients Undergoing Caesarean Section
Official title: Comparison of the Effect of Adding Midazolam Versus Fentanyl to Intrathecal Levobupivacaine in Patients Undergoing Caesarean Section
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cesarean Section Complications
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-01-31
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this study is to compare the effects of intrathecal levobupivacaine plus midazolam and levobupivacaine plus fentanyl in patients undergoing caesarean section to get a prolonged postoperative analgesic effect and less side effects


Eligibility criteria: Inclusion Criteria:

* Patients of American Society of Anaesthesiologists grades I and II ,

Exclusion Criteria:

* pre-existing neurological or spinal disease

Primary outcomes:
measure: 1st post-operative analgesic request
timeFrame: 24-hour
Secondary outcomes:
measure: duration of sensory block Total analgesic consumption
timeFrame: 24-hour
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Mohamed
Study officials:
References:
Clinical trial NCT04630314: Covered Stents in Treatment of Coronary Artery Perforation
Official title: Procedural and 1-year Outcomes Following Large Vessel Coronary Artery Perforation Treated by Covered Stents Implantation: Multicentre CRACK Registry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Perforation
Keywords: Percutaneous coronary intervention
Coronary artery perforation
Covered stent
Lead sponsor: Medical University of Silesia
Sponsor class: OTHER
First posted: 2020-11-16
Enrollment: 119
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All consecutive patients

Brief summary: Covered stents have been mainly used for treatment of potentially life-threatening coronary artery perforation and coronary artery aneurysm. Prior studies suggest that the use of covered stents improves event-free survival, enabling a life-threatening situation to be managed without emergency surgery and with significantly reduced rates of mortality, cardiac tamponade, and major adverse cardiac events. Although the devices are used for a long time, very limited study has described procedural-related outcomes with this specific technology. We therefore want to report procedural, in-hospital and long term outcomes among patients treated with the covered stents.


Eligibility criteria: Inclusion Criteria:

* Iatrogenic, peri-PCI CAP treated with covered stent implantation

Exclusion Criteria:

* CAP caused due to other cause than PCI
* PCI of other vascular territories during the same procedure

Primary outcomes:
measure: Major Adverse Cardiac Events (MACE)
timeFrame: 1 year
Secondary outcomes:
measure: Stent Thrombosis (ST)
timeFrame: 1 year
measure: Cardiac Death
timeFrame: 1 year
measure: Target Lesion Revascularization (TLR)
timeFrame: 1 year
measure: Myocardial Infarction (MI)
timeFrame: 1 year
Other outcomes:
Locations:
city: Białystok
country: Poland
facility: Department of Invasive Cardiology, Medical University of Białystok
city: Gdańsk
country: Poland
facility: First Department of Cardiology, Medical University of Gdansk
city: Katowice
country: Poland
facility: Wojciech Wańha
city: Kraków
country: Poland
facility: Second Department of Cardiology, Jagiellonian University Medical College
city: Lubin
country: Poland
facility: Miedziowe Centrum Zdrowia S.A.
city: Zabrze
country: Poland
facility: Third Department of Cardiology, Medical University of Katowice
Study officials:
References: